Status:
UNKNOWN
Impact Of Choline in Patients With NAFLD
Lead Sponsor:
Ain Shams University
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The study will be assessing the impact of choline supplementation in Non-alcoholic fatty liver disease patients using ultrasonography to show change in liver echogenicity, various laboratory tests as ...
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) has attracted increasing attention given its high prevalence, estimated at 20% to 44% in Western countries and 5% to 38% in Asia as well as its correlation wi...
Eligibility Criteria
Inclusion
- Adult Patients from 18 to 65 years.
- Gender: both males and females (age and sex matched in both groups).
- Patients diagnosed with NAFLD via ultrasound (hepatic steatosis observation on ultrasound).
- Treatment free from choline supplementation for the past 3 months prior starting the therapeutic regimen.
Exclusion
- Other liver diseases as viral hepatitis (B or C)
- Alcohol consumption more than 40 g per week for the past 12 months, and life-time cumulative consumption more than 100 kg.
- Autoimmune liver disease
- Malignancy of any nature.
- Any systemic failure (cardiovascular, renal or respiratory)
- Patients with major psychiatric illness.
- Pregnant or lactating women.
- Diabetes mellitus .
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05200156
Start Date
February 1 2022
End Date
February 1 2024
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tropical Medicine Department
Cairo, Egypt